Merck (MRK) Tops Q3 EPS by 23c; narrows forecast

Merck (NYSE: MRK) reported Q3 EPS of $2.58, $0.23 better than the analyst estimate of $2.35. Revenue for the quarter came in at $17.28 billion versus the consensus estimate of $16.98 billion.

GUIDANCE:

Merck sees FY2025 EPS of $8.93-$8.98, versus the consensus of $8.89. Merck sees FY2025 revenue of $64.5-65 billion, versus the consensus of $64.81 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Morgan Stanley Upgrades Merck (MRK) to Overweight
• Is the global equity rally broadening? UBS weighs in
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics